Cargando…

Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo

Malignant tumours often induce a fibroproliferative response in the adjacent stroma, characterized by increased expression of type I and type III procollagens. In normal tissues, fibrillar collagens normally undergo extensive intermolecular cross-linking that provides tensile strength to the tissue....

Descripción completa

Detalles Bibliográficos
Autores principales: Kauppila, S, Bode, M K, Stenbäck, F, Risteli, L, Risteli, J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362884/
https://www.ncbi.nlm.nih.gov/pubmed/10574251
http://dx.doi.org/10.1038/sj.bjc.6690743
_version_ 1782153565205168128
author Kauppila, S
Bode, M K
Stenbäck, F
Risteli, L
Risteli, J
author_facet Kauppila, S
Bode, M K
Stenbäck, F
Risteli, L
Risteli, J
author_sort Kauppila, S
collection PubMed
description Malignant tumours often induce a fibroproliferative response in the adjacent stroma, characterized by increased expression of type I and type III procollagens. In normal tissues, fibrillar collagens normally undergo extensive intermolecular cross-linking that provides tensile strength to the tissue. Here we set out to characterize collagen cross-linking in human ovarian carcinoma tissue in vivo. Biochemical and immunochemical methods were used for cross-linked telopeptides of type I and III collagens in samples of benign and malignant serous tumours. The locations and staining patterns of these proteins were visualized immunohistochemically. The contents of both total collagen and the cross-linked type I and type III collagens in the malignant samples were only about 20% of those in the benign tumours. The cross-linked telopeptide antigens derived from the collagens were smaller and more heterogeneous in size in the malignant than in the benign tumours, indicating a defective cross-linking process scarcely leading to the formation of mature cross-links in the collagen fibres in malignancy. Immunostaining revealed disorganized type I and type III collagen bundles in carcinomas. These findings suggest that the collagen cross-linking process is aberrant in malignant tumours, possibly resulting in increased susceptibility of tumour collagens for the proteolysis often associated with tumour invasion. © 1999 Cancer Research Campaign
format Text
id pubmed-2362884
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23628842009-09-10 Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo Kauppila, S Bode, M K Stenbäck, F Risteli, L Risteli, J Br J Cancer Regular Article Malignant tumours often induce a fibroproliferative response in the adjacent stroma, characterized by increased expression of type I and type III procollagens. In normal tissues, fibrillar collagens normally undergo extensive intermolecular cross-linking that provides tensile strength to the tissue. Here we set out to characterize collagen cross-linking in human ovarian carcinoma tissue in vivo. Biochemical and immunochemical methods were used for cross-linked telopeptides of type I and III collagens in samples of benign and malignant serous tumours. The locations and staining patterns of these proteins were visualized immunohistochemically. The contents of both total collagen and the cross-linked type I and type III collagens in the malignant samples were only about 20% of those in the benign tumours. The cross-linked telopeptide antigens derived from the collagens were smaller and more heterogeneous in size in the malignant than in the benign tumours, indicating a defective cross-linking process scarcely leading to the formation of mature cross-links in the collagen fibres in malignancy. Immunostaining revealed disorganized type I and type III collagen bundles in carcinomas. These findings suggest that the collagen cross-linking process is aberrant in malignant tumours, possibly resulting in increased susceptibility of tumour collagens for the proteolysis often associated with tumour invasion. © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362884/ /pubmed/10574251 http://dx.doi.org/10.1038/sj.bjc.6690743 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Kauppila, S
Bode, M K
Stenbäck, F
Risteli, L
Risteli, J
Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo
title Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo
title_full Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo
title_fullStr Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo
title_full_unstemmed Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo
title_short Cross-linked telopeptides of type I and III collagens in malignant ovarian tumours in vivo
title_sort cross-linked telopeptides of type i and iii collagens in malignant ovarian tumours in vivo
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362884/
https://www.ncbi.nlm.nih.gov/pubmed/10574251
http://dx.doi.org/10.1038/sj.bjc.6690743
work_keys_str_mv AT kauppilas crosslinkedtelopeptidesoftypeiandiiicollagensinmalignantovariantumoursinvivo
AT bodemk crosslinkedtelopeptidesoftypeiandiiicollagensinmalignantovariantumoursinvivo
AT stenbackf crosslinkedtelopeptidesoftypeiandiiicollagensinmalignantovariantumoursinvivo
AT ristelil crosslinkedtelopeptidesoftypeiandiiicollagensinmalignantovariantumoursinvivo
AT ristelij crosslinkedtelopeptidesoftypeiandiiicollagensinmalignantovariantumoursinvivo